Related references
Note: Only part of the references are listed.Vogt-Koyanagi-Harada-like Syndrome After CTLA-4 Inhibition With Ipilimumab for Metastatic Melanoma
Jason N. Crosson et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Bilateral Choroidopathy and Serous Retinal Detachments During Ipilimumab Treatment for Cutaneous Melanoma
Dimosthenis Mantopoulos et al.
JAMA OPHTHALMOLOGY (2015)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab
Elizabeth McElnea et al.
ORBIT-AN INTERNATIONAL JOURNAL ON ORBITAL DISORDERS AND FACIAL RECONSTRUCTIVE SURGERY (2014)
Orbital myositis associated with ipilimumab
M. Lecouflet et al.
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE (2013)
Melanoma-Associated Retinopathy Treated with lpilimumab Therapy
A. Audemard et al.
DERMATOLOGY (2013)
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
Kevin B. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Peter A. Prieto et al.
CLINICAL CANCER RESEARCH (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET ONCOLOGY (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
Grazia Graziani et al.
PHARMACOLOGICAL RESEARCH (2012)
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
Le Min et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Monoclonal antibody therapy-associated neurological disorders
Xavier Bosch et al.
NATURE REVIEWS NEUROLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
Troy Dillard et al.
PITUITARY (2010)
Update on Immunologic Therapy With Anti-CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their Management
Katharina C. Kaehler et al.
SEMINARS IN ONCOLOGY (2010)
Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis
David R. Minor et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
Ipilimumab: controversies in its development, utility and autoimmune adverse events
Jeffrey Weber
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab
R. L. Johnston et al.
DIGESTIVE DISEASES AND SCIENCES (2009)
Neutropenia in a Patient Treated With Ipilimumab (anti-CTLA-4 Antibody)
Mojtaba Akhtari et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events
Jeffrey Weber
ONCOLOGIST (2007)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study
AV Maker et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
Cytotoxic T-Lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer
JA Blansfield et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma
K Sanderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma - A new cause of uveitis
MR Robinson et al.
JOURNAL OF IMMUNOTHERAPY (2004)